Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer.

Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, Silver JE, Bisht A, Labiad Y, Peck RB, Lim J, Jeronimo J, Howard R, Gravitt PE, Castle PE.

J Clin Microbiol. 2010 Dec;48(12):4646-8. doi: 10.1128/JCM.01315-10. Epub 2010 Oct 6.

PMID:
20926711
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ.

J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2.

PMID:
22553244
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.

Castle PE, Solomon D, Schiffman M, Wheeler CM.

J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71.

PMID:
16030304
[PubMed - indexed for MEDLINE]
Free Article
4.

Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions.

Andersson S, Alemi M, Rylander E, Strand A, Larsson B, Sällström J, Wilander E.

Br J Cancer. 2000 Aug;83(3):307-10.

PMID:
10917543
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or=2 in a liquid-based cytology setting?

Boulet GA, Benoy IH, Depuydt CE, Horvath CA, Aerts M, Hens N, Vereecken AJ, Bogers JJ.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2992-9. doi: 10.1158/1055-9965.EPI-09-0025. Epub 2009 Oct 27.

PMID:
19861526
[PubMed - indexed for MEDLINE]
Free Article
6.

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Kjær SK, Frederiksen K, Munk C, Iftner T.

J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88. doi: 10.1093/jnci/djq356. Epub 2010 Sep 14.

PMID:
20841605
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

PMID:
16030305
[PubMed - indexed for MEDLINE]
Free Article
8.

Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma.

Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briolat J, Riethmuller D, Kantelip B, Schwarz E, Mougin C, Prétet JL.

J Clin Microbiol. 2008 Nov;46(11):3678-85. doi: 10.1128/JCM.01212-08. Epub 2008 Sep 17.

PMID:
18799702
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical significance of signal pattern of high-risk human papillomavirus using a novel fluorescence in situ hybridization assay in cervical cytology.

Ho CM, Lee BH, Chang SF, Chien TY, Huang SH, Yan CC, Cheng WF.

Clin Microbiol Infect. 2011 Mar;17(3):386-94. doi: 10.1111/j.1469-0691.2010.03186.x.

PMID:
20148921
[PubMed - indexed for MEDLINE]
10.

Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions.

Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, Costa S, Musiani M, Zerbini M.

Gynecol Oncol. 2007 Sep;106(3):549-57. Epub 2007 Jun 13.

PMID:
17568661
[PubMed - indexed for MEDLINE]
11.

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A.

J Clin Microbiol. 2011 Feb;49(2):557-64. doi: 10.1128/JCM.02147-10. Epub 2010 Dec 8.

PMID:
21147950
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.

Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.

Clin Vaccine Immunol. 2010 Sep;17(9):1315-21. doi: 10.1128/CVI.00105-10. Epub 2010 Jul 28.

PMID:
20668141
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples.

Yang YS, Smith-McCune K, Darragh TM, Lai Y, Lin JH, Chang TC, Guo HY, Kesler T, Carter A, Castle PE, Cheng S.

Clin Vaccine Immunol. 2012 Sep;19(9):1474-9. doi: 10.1128/CVI.00388-12. Epub 2012 Jul 18.

PMID:
22815148
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Increased levels of HPV16 E6*I transcripts in high-grade cervical cytology and histology (CIN II+) detected by rapid real-time RT-PCR amplification.

Kösel S, Burggraf S, Engelhardt W, Olgemöller B.

Cytopathology. 2007 Oct;18(5):290-9. Epub 2007 Jul 27.

PMID:
17662070
[PubMed - indexed for MEDLINE]
15.

Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential.

Xin CY, Matsumoto K, Yoshikawa H, Yasugi T, Onda T, Nakagawa S, Yamada M, Nozawa S, Sekiya S, Hirai Y, Shiromizu K, Fujii T, Taketani Y.

Cancer Lett. 2001 Sep 10;170(1):19-24.

PMID:
11448530
[PubMed - indexed for MEDLINE]
16.

The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.

Pillai MR, Halabi S, McKalip A, Jayaprakash PG, Rajalekshmi TN, Nair MK, Herman B.

Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):329-35.

PMID:
9162297
[PubMed - indexed for MEDLINE]
Free Article
17.

Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.

Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, Schiffman M, Wacholder S, Allen RA, Block I, Downing K, Jeronimo J, Carreon JD, Safaeian M, Brown D, Walker JL.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):113-20. doi: 10.1158/1055-9965.EPI-08-0591.

PMID:
19124488
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.

Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1268-73.

PMID:
16835322
[PubMed - indexed for MEDLINE]
Free Article
19.

A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer.

Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, Holladay EB, Kolk DP.

Clin Cancer Res. 2007 May 1;13(9):2599-605.

PMID:
17473189
[PubMed - indexed for MEDLINE]
Free Article
20.

Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population.

Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, Sekiya S, Hirai Y, Kukimoto I, Kanda T, Taketani Y.

Cancer Lett. 2000 Aug 11;156(2):159-65.

PMID:
10880765
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk